Aptevo reports 100% remission rate in Cohort 3 of Phase 1b/2 RAINIER trial for mipletamig in AML

Aptevo Therapeutics Inc.

100% remission rate (CR/CRi) in Cohort 3 with mipletamig + venetoclax + azacitidine for newly diagnosed AML unfit for intensive chemo.
No dose-limiting toxicities or cytokine release syndrome observed across all RAINIER cohorts; safety profile clean.
40% of treated patients achieved minimal residual disease (MRD)-negative status, a marker associated with improved outcomes.
Cohort 4 now enrolling at next dose level; data expected at major medical conference in Q4 2025.
Frontline AML market is multibillion-dollar; mipletamig could redefine standard of care if later-stage data confirm.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.